| protein
| interaction with PDPK1 (PDPK1 plays an important role in cell proliferation and cell cycle progression by controlling the expression of both cyclin D1 and CDKN1B  |
|
functional link between STAT1 and CDKN1B, which act in coordination to suppress the oncogenic properties of activated RAS |
|
interaction with CFL1 (cofilin expression and its regulation of CDKN1B expression is important for the control of G(1) phase progression) |
|
interacts with MCM7, a DNA replication licensing factor, to inhibit initiation of DNA replication |
|
a novel JAK2 substrate (JAK2 can directly bind and phosphorylate CDKN1B) |
|
a novel target of HIPK2 |
|
WWP1 decreases CDKN1B protein levels and CDKN1B may play a key regulatory role in WWP1-mediated cellular senescence |
|
HSPA8 interacts with both CDKN1C and CDKN1B and the subcellular localization of HSPA8 was critical to maintain HSC (hematopoietic stem cell) cycle kinetics |
|
cellular function of CDKN1B as a transcriptional regulator in association with RBL2/E2F4 complexes that could be relevant for tumorigenesis |
|
KAT2B induces CDKN1B degradation via proteasome |
|
is involved in GJA1-induced neuronal translocation and morphological transformation in the subventricular (SVZ)/intermediate zone (IZ) |
|
important role of TADA3-dependent control of CDKN1B levels in promoting cell cycle progression |
|
YWHAE regulates cardiogenesis and growth of the compact ventricular myocardium by modulating the cardiomyocyte cell cycle via both CCNE1 and CDKN1B |
|
receptor-specific function for NOTCH2 in mediating vascular smooth muscle cell growth arrest through CDKN1B |
|
inverse expression pattern of CDKN1B and F3, but also a direct regulatory link between the two proteins |
|
EXOC3 regulates cytoplasmic translocation of CDKN1B through CDKN1B phosphorylation at Thr157, thereby promoting CDKN1B degradation in the cytoplasm via interaction with COPS5 and SIAH1 and suppressing cell cycle progression |
|
SMAD2 overexpression inhibits the proliferation of junctional epithelium (JE) cells by down-regulating MYC and up-regulating CDKN2B and CDKN1B, which resulted in an increase in RB1, leading to cell-cycle arrest |
|
STMN1 is a relevant CDKN1B binding partner (cooperates with CDKN1B to control the early phase of G1 to S phase transition and this function may be of particular relevance in the context of tumor progression) |
|
UBE2L3 specifically protects CDKN1B from degradation |
|
MAST1 influences likely nervous system development by affecting neuronal differentiation through CDKN1B |
|
critical role of PUM1 mediated translational control, particularly the PUM1-CDKN1B axis, in prostate cancer cell growth and tumorigenesis |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
with CCND3 in agressive B cell lymphoma | | tumoral
|
|
| --low
|
| |
in the development and progression of oral squamous cell carcinoma and in thyroid, colon, breast, prostate and superficial bladder carcinoma | | tumoral
|
| deletion
|
|
| |
deleted in leukemia and other cancers with poor prognosis (pancreas adenocarcinoma, esophageal squamous cell carcinoma), degraded by proteasomes in gliomas | | tumoral
|
|
| --low
|
| |
(when inhibited by AKT1) in aggressive breast cancer | | tumoral
| germinal mutation
|
|
|
| |
in multiple endocrine neoplasia syndrome | | constitutional
|
|
| --low
|
| |
in both acute and end-stage heart failure | |
